Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy

Bottom line: A trial is exploring whether psilocybin-assisted therapy may be associated with reduced symptoms in individuals with persisting concussion effects.

A 22-year-old athlete sat in a quiet room, his hands shaking as he described the moment his head hit the ground. Days later, the headaches, dizziness, and memory gaps still clung to him. For millions, this is the reality of post-concussion syndrome — a condition that lingers long after the initial injury. Now, in a small but growing corner of medical research, scientists are asking: Could a single dose of psilocybin, a compound found in certain mushrooms, help the brain reset?

This is the focus of a new clinical trial led by the University of Calgary. The study is testing whether psilocybin-assisted therapy can reduce symptoms for people who haven’t recovered from a concussion. So far, it’s still in early stages — but the potential implications are already stirring interest in the field of neurorecovery.

The Science of Concussion and Its Lingering Shadows

About 10% to 30% of people who suffer a concussion experience symptoms that last for weeks, months, or even years. Known as post-concussion syndrome, these symptoms can include headaches, dizziness, and even long-term cognitive or emotional difficulties. Researchers are still trying to understand what causes this — possible factors include disrupted brain connectivity, inflammation, and changes in brain chemistry.

Standard treatments like rest, cognitive therapy, and medication often don’t resolve the problem. Some people report only partial improvement, and others find themselves stuck in a cycle of recurring symptoms. That’s where psilocybin — a compound studied for its effects on mental health — comes into play.

This trial is testing whether psilocybin can help. Participants will be randomly assigned to receive either psilocybin-assisted psychotherapy or an active control treatment. The trial is evaluating not just safety but also whether the treatment can reduce symptoms and improve quality of life.

What’s different about this trial is the use of low-dose psilocybin. Most psychedelic research uses high doses, but this approach suggests researchers are exploring how lower doses might influence mood, cognition, and neural pathways — a shift that reflects a growing understanding of how psychedelics work.

A Case That Broke the Silence

The first real-world evidence of psilocybin’s potential comes from a case report. A 22-year-old intercollegiate athlete, after a concussion, found himself trapped in a cycle of symptoms that standard treatments couldn’t break. His headaches, noise sensitivity, and cognitive fog lasted for months. Then, he took small doses of psilocybin — 250 milligrams of dried Psilocybe cubensis mushrooms, which contain about 2.5 mg of the active compound.

Within days, his symptoms changed. His headaches disappeared. His cognition improved. His emotional distress vanished. His symptom severity score dropped from 25 to 11, and he returned to full activity. This case is not just a recovery story — it’s a glimpse into what might be possible. But it’s also a reminder that this is just one person, and more data is needed.

The Road to Understanding: What the Research Shows

Broader research on psilocybin and neurological conditions is already showing promise. A review published in Europe PMC found that psilocybin has shown efficacy in treating depression, anxiety, and even alcohol use disorders. These studies suggest that psilocybin may influence the brain’s ability to rewire itself — a process known as neuroplasticity — and reduce inflammation, which is also linked to post-concussion symptoms.

Another study surveyed 175 people, including athletes and sports staff, about their attitudes toward psilocybin-assisted therapy for concussion recovery. A majority of respondents were open to the idea, even if they had never used psilocybin before. This points to a shift in perception — a growing willingness among athletes and medical professionals to consider unconventional treatments.

Still, most psilocybin research has focused on mental health, not neurological injuries. This trial is among the first to specifically target post-concussion symptoms, and its findings could offer new treatment options for millions.

Frequently Asked Questions

Q: Can psilocybin really help with concussion symptoms?
A: Early research — including a case report of an athlete who experienced significant symptom relief — suggests it may be a promising avenue. However, this is still a relatively new area of study, and more research is needed before any definitive conclusions can be drawn.

Q: Is psilocybin safe for people with concussion-related symptoms?
A: The trial is designed to test the safety and feasibility of psilocybin-assisted therapy, and so far, no adverse effects have been reported in the case report. However, safety in a broader population will be evaluated through the trial itself.

Q: Will this treatment be available for the general public?
A: That depends on the results of the trial and the regulatory approval process. Even if psilocybin is found to be effective, making it widely available will require navigating legal and ethical challenges.

Q: How long does the treatment take?
A: The trial includes a 25mg psilocybin dose followed by five weekly sessions of acceptance and commitment therapy (ACT). The exact duration may vary depending on individual needs and response to treatment.

Q: What if I’m not interested in taking psilocybin?
A: This trial is not the only option. There are many other treatments available for concussion symptoms, including cognitive therapy, physical rehabilitation, and medication. The goal of this study is to explore additional options, not to replace existing ones.

Sources

• ¶ClinicalTrials.gov: NCT06615908
• ¶Psychoactives: Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion
• ¶Europe PMC: Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
• ¶Europe PMC: The Emergence of Psilocybin in Psychiatry and Neuroscience

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.